Inventiva SA
IVAHealthcare|Biotechnology|France
$4.29
-0.21 (-4.66%)
Clinical Trials (8)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04849728 A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) | NASH - Nonalcoholic Steatohepatitis | P3 | Active | 1,000 | RCT, Double-blind | IVA337, Placebo |
| NCT05651724 Global Research Initiative for Patients Screening on MASH | MASH, MASLD | Recruiting | 10,000 | — | — | |
| NCT03008070 Phase 2b Study in NASH to Assess IVA337 | Non-Alcoholic Steatohepatitis (NASH) | P2 | Completed | 247 | RCT, Double-blind | IVA337, IVA337, Placebo |
| NCT03370653 A Study in MPS VI to Assess Safety and Efficacy of Odiparcil | Mucopolysaccharidosis VI | P2 | Completed | 20 | RCT, Double-blind | Odiparcil |
| NCT05232071 Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus | NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2 | P2 | Completed | 42 | RCT, Double-blind | IVA337, Placebo, Empagliflozin |
| NCT02503644 Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis | Scleroderma, Diffuse, Diffuse Cutaneous Systemic Sclerosis | P2 | Completed | 145 | RCT, Double-blind | IVA337, Placebo |
| NCT03459079 Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease | Nonalcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes (T2DM) | P2 | Completed | 128 | RCT, Double-blind | Lanifibranor |
| NCT03866369 Multiple Ascending Dose Phase I Study in Order to Define Lanifibranor (IVA337) Supra-thjerapeutic Dose | Healthy Subjects | P1 | Completed | 36 | RCT, Double-blind | Moxifloxacin, Placebo, Lanifibranor, Placebo |